Escherichia coli for producing L-arginine and construction method and application thereof
By heterologously expressing the ArgG gene in E. coli BL21, recombinant strain was constructed, and the problems of low yield and contamination in the existing L-arginine production methods were solved, and efficient and stable L-arginine biosynthesis was achieved. The rate is increased by 50%.
Patent Information
- Application Number
- CN202411435934.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Among the existing L-arginine production methods, the proteolytic hydrolysis method has low yields and pollutes the environment, complex chemical synthesis and toxicity, and the traditional microbial mutagenesis technology has a large and unstable workload, making it difficult to be used in large-scale industrial production.
The ArgG gene is heterologously expressed in E. coli BL21, and recombinant strains are constructed to improve the biosynthesis level of L-arginine. The expression of arginine succinate synthase gene is regulated through the PT7 promoter, thereby achieving high-efficiency of L-arginine synthesis.
The biosynthesis level of L-arginine was significantly improved, the accumulated concentration increased from 54g/L to 108g/L, and the yield was increased by 50%, achieving efficient and stable fermentation production.
Smart Images

Figure CN119020387A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bioengineering, and in particular to an Escherichia coli for producing L-arginine and a construction method and application thereof. Background Art
[0002] L-arginine is a semi-essential amino acid for the human body. It has important physiological functions in the body, such as regulating hormone secretion, treating cardiovascular diseases, promoting reproductive system development, improving immunity, etc. Therefore, it has significant commercial value in the healthcare, food, cosmetics and feed industries.
[0003] At present, the production methods of L-arginine mainly include protein hydrolysis, chemical synthesis and microbial synthesis. Hair, pig skin gelatin, etc. are rich in L-arginine and can be used as raw materials to prepare L-arginine by hydrolysis. However, the protein hydrolysis method not only has low yield and complicated operation, but also easily pollutes the environment. The chemical synthesis of L-arginine is a relatively complicated process and will produce toxic substances that pollute the environment. Compared with the chemical synthesis method, microbial synthesis of L-arginine is not only highly efficient, environmentally friendly, and has a stable production process, but also the fermentation synthesis product has high purity and basically no toxic side effects. It is considered to be the most attractive method.
[0004] Microbial synthesis of L-arginine mainly includes traditional mutagenesis and genetic engineering. A lot of research has been done on traditional mutagenesis, but this technology requires a lot of work, is highly random, has poor genetic stability, and is prone to reverse mutations, making it difficult to put into large-scale industrial production. Genetic engineering technology is to rationally transform the metabolic pathways of microorganisms to obtain recombinant engineering strains with high yields of target products.
[0005] The synthesis of L-arginine is based on L-glutamate as a substrate, and is produced by three synthetic pathways, namely, a linear pathway, a cyclic pathway, and a newly discovered pathway, and contains 7 to 8 steps of enzymatic reactions. Escherichia coli is currently used as one of the main strains for amino acid production due to its advantages such as a short growth cycle, a clear metabolic pathway, and convenient molecular manipulation. The present invention intends to develop an Escherichia coli that produces L-arginine, thereby providing technical support for the fermentation production of L-arginine. Summary of the invention
[0006] The purpose of the present invention is to provide an Escherichia coli for producing L-arginine and a construction method and application thereof to solve the problems existing in the above-mentioned prior art. The present invention constructs an Escherichia coli for producing L-arginine by heterologously expressing the ArgG gene in Escherichia coli BL21, which can improve the biosynthesis level of L-arginine, thereby providing technical support for the fermentation production of L-arginine.
[0007] To achieve the above object, the present invention provides the following solutions:
[0008] The invention provides a method for constructing an L-arginine-producing Escherichia coli, comprising the steps of introducing an argininosuccinate synthetase gene into an Escherichia coli starting strain to construct a recombinant strain that overexpresses the argininosuccinate synthetase gene, wherein the recombinant strain is the L-arginine-producing Escherichia coli.
[0009] Furthermore, the nucleotide sequence of the argininosuccinate synthetase gene is shown in SEQ ID NO.1.
[0010] Furthermore, the nucleotide sequence of the argininosuccinate synthetase gene is shown in SEQ ID NO.2.
[0011] Furthermore, the starting strain of Escherichia coli is Escherichia coli BL21.
[0012] Furthermore, the recombinant strain is constructed by transforming a recombinant plasmid containing the argininosuccinate synthetase gene into the starting Escherichia coli strain.
[0013] Furthermore, through P T7 The promoter regulates the expression of the argininosuccinate synthetase gene.
[0014] The present invention also provides an L-arginine-producing Escherichia coli constructed according to the above construction method.
[0015] The present invention also provides the use of the above-mentioned L-arginine-producing Escherichia coli in fermentation production of L-arginine.
[0016] The present invention also provides a method for producing L-arginine by fermentation, comprising the step of fermenting and culturing the above-mentioned Escherichia coli for producing L-arginine.
[0017] Further, the culture medium of the fermentation culture comprises the following components: glucose 20-40 g / L, peptone 2-10 g / L, K2HPO4 2-3 g / L, sodium gluconate 1-2 g / L, K2SO4·7H2O 2-3 g / L, FeSO4·7H2O 10-20 mg / L, choline 10-20 mg / L, vitamin B1 (VB1) 1-3 mg / L, vitamin B3 (VB3) 1-3 mg / L, vitamin B5 (VB5) 1-3 mg / L, vitamin B12 (VB12) 1-3 mg / L and vitamin H (VH) 1-3 mg / L, pH 7.0-7.2;
[0018] The fermentation culture conditions are as follows: the fermentation temperature is 33-37° C., the carbon dioxide release rate is controlled at 105±16 mmol / L / h by sugar supplementation, and the residual glucose concentration in the fermentation liquid is controlled at 0.3±0.2 g / L.
[0019] The present invention discloses the following technical effects:
[0020] The present invention has found that in the L-arginine metabolic pathway of Escherichia coli, argininosuccinate synthetase (encoded by the ArgG gene) is one of the key rate-limiting enzymes. The efficient expression of the enzyme can relieve the feedback regulation mechanism of the L-arginine synthesis pathway and achieve a balance between strain growth and L-arginine production. The present invention constructs an Escherichia coli that produces L-arginine by heterologously expressing the ArgG gene in Escherichia coli BL21, which can improve the biosynthesis level of L-arginine. Among them, the overexpression of the argininosuccinate synthetase gene ArgG derived from Stretococcus thermophilus in Escherichia coli BL21 can significantly improve the biosynthesis level of L-arginine, and the L-arginine accumulation concentration is increased from 54g / L to 108g / L, and the yield of L-arginine is increased by 50%. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0022] Figure 1 This is a statistical chart of L-arginine production by genetically engineered Escherichia coli strains CY517-01, CY517-02, and CY517-03. DETAILED DESCRIPTION
[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0024] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0025] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0026] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0027] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0028] Example 1
[0029] The construction of Escherichia coli genetically engineered bacteria CY517-01, the specific construction method is as follows:
[0030] First, the codon-optimized argininosuccinate synthase gene ArgG (SEQ ID NO.1) of Stretococcus thermophilus was overexpressed in Escherichia coli BL21. Specifically, the heterologous gene was digested with Not I and EcoR I restriction endonucleases and then ligated to the expression plasmid pET28 that was also digested with the two restriction endonucleases. T7 The promoter regulates the expression of the heterologous gene to obtain a recombinant plasmid. The recombinant plasmid is transformed into Escherichia coli BL21, and positive clones are screened to obtain the genetic engineering strain CY517-01.
[0031] SEQ ID NO.1:
[0032]
[0033] Example 2
[0034] The construction of Escherichia coli genetically engineered bacteria CY517-02, the specific construction method is as follows:
[0035] First, the codon-optimized argininosuccinate synthase gene ArgG (SEQ ID NO. 2) of Bacillus subtilis was overexpressed in Escherichia coli BL21. Specifically, the heterologous gene was digested with Not I and EcoR I restriction endonucleases and then linked to the expression plasmid pET28 that was also digested with these two restriction endonucleases, and then expressed in the pET28 plasmid. T7 The promoter regulates the expression of the heterologous gene to obtain a recombinant plasmid. The recombinant plasmid is transformed into Escherichia coli BL21, and positive clones are screened to obtain the genetic engineering strain CY517-02.
[0036] SEQ ID NO.2:
[0037]
[0038] Comparative Example 1
[0039] The construction of Escherichia coli genetically engineered bacteria CY517-03, the specific construction method is as follows:
[0040] First, the codon-optimized argininosuccinate synthase gene ArgG (SEQ ID NO. 3) of Pseudomonas entomophila was overexpressed in Escherichia coli BL21. Specifically, the heterologous gene was digested with Not I and EcoR I restriction endonucleases and then ligated to the expression plasmid pET28 that was also digested with these two restriction endonucleases. T7 The promoter regulates the expression of the heterologous gene to obtain a recombinant plasmid. The recombinant plasmid is transformed into Escherichia coli BL21, and positive clones are screened to obtain the genetic engineering strain CY517-03.
[0041] SEQ ID NO.3:
[0042]
[0043] Example 3
[0044] The strain CY517-01 constructed in Example 1, the strain CY517-02 constructed in Example 2, and the strain CY517-03 constructed in Comparative Example 1 were fermented and cultured for 2 days.
[0045] The fermentation culture conditions are as follows: the fermentation temperature is 33-37°C, the carbon dioxide release rate is controlled at 105±16mmol / L / h by sugar supplementation, and the residual glucose concentration in the fermentation liquid is controlled at 0.3±0.2g / L.
[0046] The fermentation medium was: glucose 30 g / L, peptone 10 g / L, K2HPO4 3 g / L, sodium gluconate 1 g / L, K2SO4·7H2O 2 g / L, FeSO4·7H2O 15 mg / L, choline 15 mg / L, VB12 mg / L, VB32 mg / L, VB52 mg / L, VB122 mg / L and VH 2 mg / L, pH 7.0.
[0047] After the fermentation culture was completed, the L-arginine content in each fermentation broth was detected. The results are shown in Figure 1 The results showed that overexpression of the argininosuccinate synthetase gene ArgG from Stretococcus thermophilus in Escherichia coli BL21 could significantly increase the biosynthesis level of L-arginine, with the accumulation concentration of L-arginine increasing from 54 g / L to 108 g / L and the yield of L-arginine increasing by 100%.
[0048] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A method for constructing an Escherichia coli for producing L-arginine, characterized in that: The method comprises the steps of introducing the argininosuccinate synthetase gene into the starting strain of Escherichia coli to construct a recombinant strain over-expressing the argininosuccinate synthetase gene, wherein the recombinant strain is the Escherichia coli producing L-arginine.
2. The construction method according to claim 1, characterized in that: The nucleotide sequence of the argininosuccinate synthetase gene is shown in SEQ ID NO.
1.
3. The construction method according to claim 1, characterized in that: The nucleotide sequence of the argininosuccinate synthetase gene is shown in SEQ ID NO.
2.
4. The construction method according to claim 1, characterized in that: The starting strain of Escherichia coli is Escherichia coli BL21.
5. The construction method according to claim 1, characterized in that: The recombinant strain is constructed by transforming the recombinant plasmid containing the argininosuccinate synthetase gene into the starting Escherichia coli strain.
6. The construction method according to claim 5, characterized in that: By P T7 The promoter regulates the expression of the argininosuccinate synthetase gene.
7. An L-arginine-producing Escherichia coli constructed according to the construction method according to any one of claims 1 to 6.
8. Use of the L-arginine-producing Escherichia coli according to claim 7 in fermentation production of L-arginine.
9. A method for producing L-arginine by fermentation, characterized in that: The method comprises the step of fermenting and culturing the L-arginine-producing Escherichia coli according to claim 7.
10. The method according to claim 9, characterized in that The culture medium for the fermentation culture comprises the following components: 20-40 g / L glucose, 2-10 g / L peptone, 2-3 g / L K2HPO4, 1-2 g / L sodium gluconate, 2-3 g / L K2SO4·7H2O, 10-20 mg / L FeSO4·7H2O, 10-20 mg / L choline, 1-3 mg / L vitamin B11-3 mg / L vitamin B31-3 mg / L vitamin B51-3 mg / L vitamin B121-3 mg / L and 1-3 mg / L vitamin H.
Citation Information
Patent Citations
Gene GhASS1 for improving salt tolerance of Escherichia coli and preparation of gene GhASS1 as well as protein coded by gene GhASS1
CN104059928A
Genetically engineered bacterium for producing L-arginine and construction method and application thereof
CN110964683A
